Mawi DNA Technologies Announces Partnership with FUJIFILM
4.10.2021 16:00:00 EEST | Business Wire | Press release
Mawi DNA Technologies (Mawi) has signed a distribution agreement with FUJIFILM Wako Pure Chemical Corporation, a leader in the biomedical industry, to deliver Mawi’s iSWAB biosampling technologies to Japan.
“The collaboration with FUJIFILM Wako to provide iSWAB Microbiome-EL sample collection tubes for molecular testing of COVID-19 by PCR and LAMP based assay allows us to offer a valuable solution in the Japanese market,” said Atsushi Yanai, Asia Pacific Business Development at Mawi. “Being able to offer the collection without the need for an RNA Extraction step complements the WAKO Genomics product range, a valuable solution in the Japanese market and to society.”
FUJIFILM will be an authorized agent and distributor for Mawi products in Japan to detect viruses such as COVID-19.
“We are extremely grateful for the opportunity to partner with FUJIFILM, a respected organization with access to key customers in the Japanese market,” added Jerome David, VP of Sales and Marketing at Mawi. “We are confident that this initial partnership around our iSWAB-Microbiome-EL technology for extraction-less detection of SARS-CoV-2 RNA in patient samples will lead to additional opportunities for our entire portfolio of biosample collection products.”
About FUJIFILM Wako Pure Chemical Corporation
FUJIFILM Wako Pure Chemical Corporation is a comprehensive laboratory chemicals manufacturer contributing to a number of cutting-edge research fields. Over time, the company has developed and manufactured high-quality products and expanded its businesses to include specialty chemicals and clinical diagnostic reagents. For more information, visit https://www.fujifilm.com/ffwk/en.
About Mawi DNA Technologies
Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. The company’s flagship product iSWAB-DNA is the only sample collection product on the market proven to produce a high quality DNA sample with low bacterial DNA content. Mawi also supplies products for collection of RNA, microbiome, intact cells, and whole blood. At Mawi, The Future of Biosampling is Here™. For more information, visit http://www.mawidna.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005344/en/
Contact information
Media Contact:
Susan Tellem, APR, RN, BSN
310-313-3444 x1, Susan@tellemgrodypr.com
Investors:
Jerome David, VP of Sales and Marketing
510-256-5186, j.david@mawidna.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Adds Collaborating Firm in Uzbekistan20.10.2026 16:30:00 EEST | Press release
Andersen Consulting expands its cybersecurity and business transformation capabilities through a Collaboration Agreement with Algoruni, a consulting firm based in Uzbekistan. Algoruni advises organizations on building cyber resilience, while addressing broader management, regulatory, and sustainability priorities. Operating out of Tashkent, the firm’s services span cybersecurity strategy and data protection, corporate governance and operational improvement, and ESG strategy and reporting, with an emphasis on practical solutions tailored to each client’s circumstances. “Every organization faces a different combination of risks and opportunities, which is why we believe effective solutions must start with the realities of the business,” said Alisher Zaynutdinov, managing director of Algoruni. “Becoming a collaborating firm of Andersen Consulting allows us to pair this approach with broader international resources and perspectives, giving us new ways to help clients turn complex challenge
International AI Strategist and Author Katie King to Keynote IAMPHENOM Europe 202620.10.2026 16:30:00 EEST | Press release
Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. Phenom also unveiled the conference agenda, which centres on the decisions European HR leaders face right now: turning AI, agents and automation into business outcomes, deploying tech with a compliant-first approach, and redesigning roles and skills for the future workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020028392/en/ Phenom announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. Phenom also unveiled the conference agenda, which centres on the
Inaugural Future Health Impact Challenge Documentary Released as Expressions of Interest Open for Second Challenge20.10.2026 16:26:00 EEST | Press release
Future Health – A Global Initiative by Abu Dhabi today premiered a documentary film about the inaugural Future Health Impact Challenge during the first day of the Abu Dhabi Future Health Summit. The film’s global launch, alongside the announcement of the second Challenge connects the Challenge’s initial results with its next phase with Expressions of Interest now open for the second edition. Delivered in collaboration with MIT Solve, the inaugural Impact Challenge demonstrates the transformative power of innovative solutions that accelerate the shift from reactive to anticipatory healthcare systems. With scenes filmed in Kigali, Medellín, São Paulo, Boston, and Abu Dhabi, the film shares personal commentary from the founders, local perspectives of the solutions in action, and insight from Future Health and MIT Solve. It follows the winner and two distinguished finalists as they turn signals from frontline consultations, mosquito surveillance, and routine blood tests into information th
WETEX 2026 attracts 60 sponsoring institutions and companies from the UAE and abroad20.10.2026 16:19:00 EEST | Press release
Dubai Electricity and Water Authority (DEWA) is organising the 28th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 20 to 22 October 2026 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020867659/en/ WETEX 2026 attracts 60 sponsoring institutions and companies from the UAE and abroad (Graphic: AETOSWire) “WETEX reflects the forward-looking vision of His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, and His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, to leverage innovation and advanced global technologies, including digital transformation, artificial intelligence (AI) and smart infrastructure, to strengthen the sustainability and resilience of the water and energy sectors while encouraging climate action,” said HE Saeed Mohammed Al Tayer, MD & CEO of DEWA and Founder and
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 202620.10.2026 16:02:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant’s public-private partners using the company’s technologies and/or real-world data, underscoring the wide adoption of its platform across the research community. “At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom